Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials

Elizabeth O’Donnell, MD, provides a brief overview of key findings from the MAIA, IMROZ, BENEFIT, and CEPHEUS trials, highlighting significant developments in the treatment of transplant-ineligible patients with newly diagnosed multiple myeloma.

EP: 1.Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients

Now Viewing

EP: 2.Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials

EP: 3.Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

EP: 4.Optimizing Regimens and Managing Adverse Events in TIE NDMM

EP: 5.Looking Ahead and Key Takeaways

EP: 6.Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients

EP: 7.Overview of PERSEUS, IsKia, and GMMG-HD7

EP: 8.Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM

1. Please provide a brief overview of key findings from the below trials, such as MAIA, IMROZ, BENEFIT, and CEPHEUS.

Related Videos